RoosterBio selects GenCure as its preferred manufacturer to leverage its scalable 
technology platform, accelerating the initiation of first-in-man studies
October 2, 2017

Biotech organizations RoosterBio Inc and GenCure announced today that they are expanding their existing collaboration by providing end-to-end solutions for hMSC (human bone marrow-derived mesenchymal stromal cell)-based therapeutic technologies. This biomanufacturing solution unites clinically relevant starting and ancillary materials with a scalable manufacturing process to deliver unprecedented adult cell manufacturing efficiencies. This expanded collaboration aims to shorten development timelines, simplify technology transfers, and deliver commercially viable cost structures, thereby to accelerate regenerative medicine removing years and millions of dollars from current commercial pathways.